Trial Profile
A Phase 1, Single-Part, 6-Period, Sequential, Non-Randomized, Open-Label Study Designed to Evaluate the Pharmacokinetic Profile of Tolcapone Following Administration of Modified Release Prototype Formulations and an Experimental Divided Dose Regimen in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Feb 2019
Price :
$35
*
At a glance
- Drugs Tolcapone (Primary)
- Indications Amyloid polyneuropathy
- Focus Pharmacokinetics
- Sponsors Corino Therapeutics
- 30 Jan 2019 Status changed from active, no longer recruiting to completed.
- 23 Aug 2018 New trial record